CRISPR Therapeutics - CRSP EV/Sales Multiple

Official company branding of CRISPR Therapeutics Inc (CRSP)

CRISPR Therapeutics AG (CRSP) is leading a biological breakthrough by correcting genetic defects. The EV/Sales dynamics on the GURU.Markets daily price chart reflect this progress, where 90708.78 marks a new level. Resilience to macro shocks is driven by liquidity rather than GDP. The steady leadership of Samarth Chattopadhyay is successfully commercializing the first therapies, confirming the asset's fundamental reliability.

CRSP - CRISPR Therapeutics EV/Sales Multiple over the range 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for CRISPR Therapeutics (CRSP)

- cash balance and cash flow data:
Fundamental company valuation:CRSP (CRISPR Therapeutics AG)
Mass-produced product of crisprtx.com

To qualitatively assess assets, an investor must compare the total enterprise value with annual revenue, excluding the impact of debt load. By analyzing current EV/Sales dynamics, one can determine the market overvaluation of CRISPR Therapeutics AG (CRSP), given that geopolitical instability and complexities regarding the cross-border logistics of biomaterials directly affect the commercialization efficiency of its innovative developments.

Competitor analysis for CRISPR Therapeutics AG

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio genedx.com (WGS)|EV/Sales Multiple ultragenyx.com (RARE)|EV/Sales Multiple BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Enterprise Value-to-Revenue Multiple|twistbioscience.com - EV/Sales Multiple|10x Genomics, Inc. - Enterprise Value-to-Revenue Coefficient|NTLA (Intellia Corp) - Company Value to Revenue|Company Value to Revenue stoketherapeutics.com|Company Value to Revenue BLFS|Company Value to Revenue Wave Life Sciences Corp (WVE)|EV/Sales Multiple MAZE|Total Company Value-to-Revenue Ratio Sionna Therapeutics Inc|Enterprise Value-to-Revenue Ratio Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Enterprise Value-to-Revenue Multiple|QURE - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple